NASDAQ
0.14USD
-0.02 (-10.83%)
We have scored 66 news catalysts on Gossamer Bio, Inc. (GOSS) over the past 12 months. The biggest single-day move next to one of them came May 22, 2026, when GOSS closed +4.6%: “Wix.com (WIX) 27% Drop Prompts Investor Scrutiny -- Hagens Berman Investigating Unanticipated Spike in Operating Expenses”. Coverage across the window leans negative (average ticker sentiment −0.76). Most of the impact sits in price momentum and earnings revision trend.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
69.6M
P/E
—
EPS
—
Beta
2.00
52W range
0.1402-309.6
Day range
0.14–0.16
Open
0.15
Prev close
0.16
Volume
13M
Avg volume
23.2M
Dividend
0.00
IPO
2019-02-08
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Gossamer Bio, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Gossamer Bio, Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for GOSS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
